Literature DB >> 21614632

[Standard treatment for myositis and muscular dystrophies].

J Schmidt1, M Vorgerd.   

Abstract

We summarize the current therapeutic strategies and options in inflammatory myositis and the muscular dystrophies. In myositis, the therapeutic options include basic therapy with glucocorticosteroids and other standard immunosuppressive agents, and in individual cases escalating treatment with chemotherapy or monoclonal antibodies. The exact therapeutic sequence should be performed depending on the type of myositis and the response to immunosuppression.At present, there are still no effective causative interventions to significantly alter the progression of the muscular dystrophies. However, first gene therapy clinical studies have been started in some forms of muscular dystrophy which may open a new field of therapeutic options. Most patients with myositis or muscular dystrophy need symptom-oriented therapies which include physical therapy, adequate cardiorespiratory treatment and orthopedic interventions. In the future novel immunosuppressive options may be available in patients with myositis and possibly causative strategies in the muscular dystrophies.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21614632     DOI: 10.1007/s00115-010-2970-3

Source DB:  PubMed          Journal:  Nervenarzt        ISSN: 0028-2804            Impact factor:   1.214


  29 in total

1.  Anti-T-lymphocyte globulin treatment in inclusion body myositis: a randomized pilot study.

Authors:  C Lindberg; E Trysberg; A Tarkowski; A Oldfors
Journal:  Neurology       Date:  2003-07-22       Impact factor: 9.910

Review 2.  Creatine for treating muscle disorders.

Authors:  R A Kley; M Vorgerd; M A Tarnopolsky
Journal:  Cochrane Database Syst Rev       Date:  2007-01-24

3.  Treatment of Duchenne muscular dystrophy with ciclosporin A: a randomised, double-blind, placebo-controlled multicentre trial.

Authors:  Janbernd Kirschner; Joachim Schessl; Ulrike Schara; Bernd Reitter; Georg M Stettner; Elke Hobbiebrunken; Ekkehard Wilichowski; Günther Bernert; Simone Weiss; Florian Stehling; Gert Wiegand; Wolfgang Müller-Felber; Simone Thiele; Ulrike Grieben; Maja von der Hagen; Jürg Lütschg; Claudia Schmoor; Gabriele Ihorst; Rudolf Korinthenberg
Journal:  Lancet Neurol       Date:  2010-08-26       Impact factor: 44.182

Review 4.  Polymyositis and dermatomyositis.

Authors:  Marinos C Dalakas; Reinhard Hohlfeld
Journal:  Lancet       Date:  2003-09-20       Impact factor: 79.321

5.  Pathomechanisms of inflammatory myopathies: recent advances and implications for diagnosis and therapies.

Authors:  Jens Schmidt; Marinos C Dalakas
Journal:  Expert Opin Med Diagn       Date:  2010-03-29

Review 6.  Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management.

Authors:  Katharine Bushby; Richard Finkel; David J Birnkrant; Laura E Case; Paula R Clemens; Linda Cripe; Ajay Kaul; Kathi Kinnett; Craig McDonald; Shree Pandya; James Poysky; Frederic Shapiro; Jean Tomezsko; Carolyn Constantin
Journal:  Lancet Neurol       Date:  2009-11-27       Impact factor: 44.182

Review 7.  Evaluation and treatment of inflammatory myopathies.

Authors:  A A Amato; R J Barohn
Journal:  J Neurol Neurosurg Psychiatry       Date:  2009-10       Impact factor: 10.154

8.  Inflammation and response to steroid treatment in limb-girdle muscular dystrophy 2I.

Authors:  N Darin; A-K Kroksmark; A-C Ahlander; A-R Moslemi; A Oldfors; M Tulinius
Journal:  Eur J Paediatr Neurol       Date:  2007-04-18       Impact factor: 3.140

9.  A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis.

Authors:  M C Dalakas; I Illa; J M Dambrosia; S A Soueidan; D P Stein; C Otero; S T Dinsmore; S McCrosky
Journal:  N Engl J Med       Date:  1993-12-30       Impact factor: 91.245

10.  Fukutin gene mutations in steroid-responsive limb girdle muscular dystrophy.

Authors:  Caroline Godfrey; Diana Escolar; Martin Brockington; Emma M Clement; Rachael Mein; Cecilia Jimenez-Mallebrera; Silvia Torelli; Lucy Feng; Susan C Brown; Caroline A Sewry; Mary Rutherford; Yehuda Shapira; Stephen Abbs; Francesco Muntoni
Journal:  Ann Neurol       Date:  2006-11       Impact factor: 10.422

View more
  2 in total

Review 1.  [Myositides: What is the current situation?].

Authors:  K M Rösler; O Scheidegger
Journal:  Z Rheumatol       Date:  2015-08       Impact factor: 1.372

Review 2.  Diagnosis, pathogenesis and treatment of myositis: recent advances.

Authors:  P-O Carstens; J Schmidt
Journal:  Clin Exp Immunol       Date:  2014-03       Impact factor: 4.330

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.